Research programme: cell cycle regulation - Pfizer

Drug Profile

Research programme: cell cycle regulation - Pfizer

Latest Information Update: 19 Jan 2009

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pfizer
  • Class Piperazines; Pyridines; Pyridones; Small molecules
  • Mechanism of Action Cyclin-dependent kinase 4 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 19 Jan 2009 Preclinical development in cancer is still ongoing in the US
  • 01 Mar 2005 Syrrx has been acquired by Takeda
  • 30 Sep 2004 This programme is still in active development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top